Clinical Trial

Study of TGM-312-SC01 in Healthy Participants and Adults With MASH

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) effects of single ascending doses of TGM-312-SC01 in healthy adults and multiple ascending doses in patients with metabolic dysfunction-associated steatohepatitis (MASH).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-02-16; most recent amendment 2026-05-18.
Status change: Not Yet Recruiting → Recruiting 2026-03-23
Trial Details
NCT Number NCT07427680
Lead Sponsor Tangram Therapeutics Plc
Conditions Healthy Participants, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Enrollment 99 participants
Start Date 2026-03-03
Primary Completion 2028-03 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-19